Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances

Brian Scott Alper, Gary Foster, Lehana Thabane, Alex Rae-Grant, Meghan Malone-Moses, Eric Manheimer, Brian Scott Alper, Gary Foster, Lehana Thabane, Alex Rae-Grant, Meghan Malone-Moses, Eric Manheimer

Abstract

Objectives: Alteplase is commonly recommended for acute ischaemic stroke within 4.5 hours after stroke onset. The Third European Cooperative Acute Stroke Study (ECASS III) is the only trial reporting statistically significant efficacy for clinical outcomes for alteplase use 3-4.5 hours after stroke onset. However, baseline imbalances in history of prior stroke and stroke severity score may confound this apparent finding of efficacy. We reanalysed the ECASS III trial data adjusting for baseline imbalances to determine the robustness or sensitivity of the efficacy estimates.

Design: Reanalysis of randomised placebo-controlled trial. We obtained access to the ECASS III trial data and replicated the previously reported analyses to confirm our understanding of the data. We adjusted for baseline imbalances using multivariable analyses and stratified analyses and performed sensitivity analysis for missing data.

Setting: Emergency care.

Participants: 821 adults with acute ischaemic stroke who could be treated 3-4.5 hours after symptom onset.

Interventions: Intravenous alteplase (0.9 mg/kg of body weight) or placebo.

Main outcome measures: The original primary efficacy outcome was modified Rankin Scale (mRS) score 0 or 1 (ie, being alive without any disability) and the original secondary efficacy outcome was a global outcome based on a composite of functional end points, both at 90 days. Adjusted analyses were only reported for the primary efficacy outcome and the original study protocol did not specify methods for adjusted analyses. Our adjusted reanalysis included these outcomes, symptom-free status (mRS 0), dependence-free status (mRS 0-2), mortality (mRS 6) and change across the mRS 0-6 spectrum at 90 days; and mortality and symptomatic intracranial haemorrhage at 7 days.

Results: We replicated previously reported unadjusted analyses but discovered they were based on a modified interpretation of the National Institutes of Health Stroke Scale (NIHSS) score. The secondary efficacy outcome was no longer significant using the original NIHSS score. Previously reported adjusted analyses could only be replicated with significant effects for the primary efficacy outcome by using statistical approaches not reported in the trial protocol or statistical analysis plan. In analyses adjusting for baseline imbalances, all efficacy outcomes were not significant, but increases in symptomatic intracranial haemorrhage remained significant.

Conclusions: Reanalysis of the ECASS III trial data with multiple approaches adjusting for baseline imbalances does not support any significant benefits and continues to support harms for the use of alteplase 3-4.5 hours after stroke onset. Clinicians, patients and policymakers should reconsider interpretations and decisions regarding management of acute ischaemic stroke that were based on ECASS III results.

Trial registration number: NCT00153036.

Keywords: emergency medicine; stroke.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Hacke W, Kaste M, Bluhmki E, et al. . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29. 10.1056/NEJMoa0804656
    1. Powers WJ, Rabinstein AA, Ackerson T, et al. . 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2018;49:e46–110. 10.1161/STR.0000000000000158
    1. Lansberg MG, O'Donnell MJ, Khatri P, et al. . Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ED: American College of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e601S–36.
    1. Brown MD, Burton JH, Nazarian DJ, et al. . American College of emergency physicians (ACEP) clinical policies Subcommittee (writing Committee) on use of intravenous tPA for ischemic stroke. Clinical policy: use of intravenous tissue plasminogen activator for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2015;66:322–33.
    1. National Institute for Health and Care Excellence Alteplase for treating acute ischemic stroke. technology appraisal guidance. No. TA264, 2012. Available:
    1. AD X, Wang YJ, Wang DZ. Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese stroke therapy expert panel. CNS Neurosci Ther 2013;19:543–8.
    1. European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee Chapter 9. Ischaemic stroke and transient ischaemic attack In: Gilhus NE, Barnes MP, Bainin M, eds European Handbook of neurological management. 1 2nd ed., 2011: 101–58.
    1. Santé HAde. Stroke: early management (alert, prehospital phase, initial Hospital phase, indications for thrombolysis). clinical practice guideline, 2009. Available:
    1. Minematsu K, Toyoda K, Hirano T, et al. . Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan stroke Society. Journal of Stroke and Cerebrovascular Diseases 2013;22:571–600. 10.1016/j.jstrokecerebrovasdis.2013.04.001
    1. National Stroke Foundation (Australia) Clinical guidelines for stroke management, 2017. Available:
    1. Bryer A, Connor M, Haug P, et al. . South African guideline for management of ischaemic stroke and transient ischaemic attack 2010: a guideline from the South African stroke Society (SASS) and the SASS writing Committee. S Afr Med J 2010;100:747–78. 10.7196/SAMJ.4422
    1. Casaubon LK, Boulanger JM, Blacquiere D, et al. . Heart and stroke Foundation of Canada Canadian stroke best practices Advisory Committee. Canadian stroke best practice recommendations (CSBPR): hyperacute stroke care guidelines, update 2015. Int J Stroke 2015;10:924–40.
    1. Shy BD. Implications of ECASS III error on emergency department treatment of ischemic stroke. J Emerg Med 2014;46:385–6. 10.1016/j.jemermed.2012.05.014
    1. Hill MD, Yiannakoulias N, Jeerakathil T, et al. . The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2015;2004:62.
    1. Hier DB, Foulkes MA, Swiontoniowski M, et al. . Stroke recurrence within 2 years after ischemic infarction. Stroke 1991;22:155–61. 10.1161/01.STR.22.2.155
    1. Bluhmki E, Chamorro Ángel, Dávalos A, et al. . Stroke treatment with alteplase given 3·0–4·5 H after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. The Lancet Neurology 2009;8:1095–102. 10.1016/S1474-4422(09)70264-9
    1. Thabane L, Mbuagbaw L, Zhang S, et al. . A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol 2013;13:92 10.1186/1471-2288-13-92
    1. Morris TP, Kahan BC, White IR. Choosing sensitivity analyses for randomised trials: principles. BMC Med Res Methodol 2014;14:11 10.1186/1471-2288-14-11
    1. de Souza RJ, Eisen RB, Perera S, et al. . Best (but oft-forgotten) practices: sensitivity analyses in randomized controlled trials. Am J Clin Nutr 2016;103:5–17. 10.3945/ajcn.115.121848
    1. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk DIFFERENCES1. Am J Epidemiol 1986;123:174–84. 10.1093/oxfordjournals.aje.a114212
    1. Greenland S. Model-Based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004;160:301–5. 10.1093/aje/kwh221
    1. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199–200. 10.1093/aje/kwi188
    1. Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc 1989;84:1024–32. 10.1080/01621459.1989.10478868
    1. SAS Institute Inc SAS/STAT version 9. Cary, NC: SAS Institute Inc, 2013.
    1. Lyden P. Using the National Institutes of health stroke scale: a cautionary tale. Stroke 2017;48:513–9.
    1. Alper BS, Malone-Moses M, McLellan JS, et al. . Thrombolysis in acute ischaemic stroke: time for a rethink? BMJ 2015;350:h1795.
    1. Emberson J, Lees KR, Lyden P, et al. . Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. The Lancet 2014;384:1929–35. 10.1016/S0140-6736(14)60584-5
    1. Lees KR, Bluhmki E, von Kummer R, et al. . Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, Atlantis, NINDS, and epithet trials. The Lancet 2010;375:1695–703. 10.1016/S0140-6736(10)60491-6
    1. Sandercock P, Wardlaw JM, IST-3 Collaborative Group, . et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 hours of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352–63.
    1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–8. 10.1056/NEJM199512143332401
    1. Friedman HS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1996;334:1405–6.
    1. Koroshetz WJ. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1996;334:1405–6.
    1. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the “brain attack” campaign. BMJ 2002;324:723–9.
    1. Alper BS, Brown CB. Expanding recombinant tissue plasminogen activator time window is premature. Stroke 2009;40:e632 10.1161/STROKEAHA.109.560615

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit